Volume 25, Number 11—November 2019
Research
Serosurvey for Influenza D Virus Exposure in Cattle, United States, 2014–2015
Simone Silveira, Shollie M. Falkenberg
, Bryan S. Kaplan, Beate Crossley, Julia F. Ridpath, Fernando B. Bauermann, Charles P. Fossler, David A. Dargatz, Rohana P. Dassanayake, Amy L. Vincent, Cláudio W. Canal, and John D. Neill
, Bryan S. Kaplan, Beate Crossley, Julia F. Ridpath, Fernando B. Bauermann, Charles P. Fossler, David A. Dargatz, Rohana P. Dassanayake, Amy L. Vincent, Cláudio W. Canal, and John D. Neill
Table
Serosurveillance results for influenza D virus in cattle, by region and state, United States, 2014–2015*
| Region and state | No. samples | Seropositive rate, %† | GMT (range)‡ |
|---|---|---|---|
| Mountain West | |||
| Idaho | 187 | 87.2 | 230 (40–1,280) |
| Montana | 86 | 84.9 | 270 (40–1,280) |
| Colorado | 78 | 88.5 | 330 (40–1,280) |
| Utah | 29 | 79.3 | 240 (80–1,280) |
| Wyoming | 24 | 79.2 | 460 (80–1,280) |
| Arizona | 21 | 57.1 | 140 (40–1,280) |
| New Mexico | 16 | 93.8 | 210 (40–1,280) |
| Nevada | 8 | 75.0 | 250 (80–1,280) |
| Total |
449 |
84.6 |
260 (40–1,280) |
| Upper Midwest | |||
| Nebraska | 125 | 91.2 | 260 (40–1,280) |
| Iowa | 101 | 92.1 | 270 (40–1,280) |
| Kansas | 98 | 86.7 | 300 (40–1,280) |
| Missouri | 94 | 86.2 | 220 (40–1,280) |
| South Dakota | 87 | 90.8 | 300 (40–1,280) |
| Minnesota | 83 | 89.2 | 280 (40–1,280) |
| Wisconsin | 79 | 84.8 | 250 (40–1,280) |
| Ohio | 47 | 48.9 | 130 (40–640) |
| North Dakota | 41 | 56.1 | 400 (40–1,280) |
| Indiana | 27 | 37.0 | 120 (40–640) |
| Michigan | 19 | 63.2 | 190 (40–1,280) |
| Illinois | 6 | 83.3 | 160 (80–320) |
| Total |
807 |
84.0 |
260 (40–1,280) |
| South Central | |||
| Oklahoma | 102 | 79.4 | 230 (40–1,280) |
| Texas | 48 | 75.0 | 170 (40–1,280) |
| Total |
150 |
78.0 |
210 (40–1,280) |
| Pacific West | |||
| California | 166 | 77.7 | 190 (40–1,280) |
| Oregon | 42 | 76.2 | 300 (40–1,280) |
| Washington | 40 | 72.5 | 230 (40–1,280) |
| Total |
248 |
76.7 |
210 (40–1,280) |
| Southeast | |||
| Arkansas | 24 | 83.3 | 180 (40–640) |
| Virginia | 23 | 43.5 | 130 (40–640) |
| Kentucky | 22 | 68.2 | 310 (80–1,280) |
| Florida | 21 | 57.1 | 170 (40–1,280) |
| Alabama | 19 | 68.4 | 140 (40–1,280) |
| Tennessee | 10 | 50.0 | 240 (80–640) |
| West Virginia | 9 | 33.3 | 200 (80–640) |
| Louisiana | 7 | 42.9 | 160 (80–320) |
| Mississippi | 4 | 25.0 | 80 (80–80) |
| Georgia | 4 | 75.0 | 160 (80–320) |
| Total |
143 |
59.5 |
180 (40–1,280) |
| Northeast | |||
| Pennsylvania | 61 | 50.8 | 120 (40–1,280) |
| New York | 61 | 45.9 | 110 (40–1,280) |
| Vermont | 47 | 51.1 | 110 (40–640) |
| Connecticut | 11 | 0 | 0 |
| Maryland | 7 | 71.4 | 110 (40–1,280) |
| Massachusetts | 5 | 60.0 | 80 (80–80) |
| New Hampshire | 3 | 66.7 | 80 (80–80) |
| Total | 195 | 47.7 | 110 (40–1,280) |
*GMT, geometric mean titer.
†Seropositive rate was calculated using those samples with hemagglutination inhibition titer ≥40.
‡GMT was calculated using those samples with HI titer ≥40. Lowest and highest titers were measured from those samples with HIT titer >40.
Page created: October 15, 2019
Page updated: October 15, 2019
Page reviewed: October 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.